logo-loader
VolitionRx

VolitionRX hosts Capital Markets Day at the NYSE

VolitionRx (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive Investors the life sciences company has organized a Capital Markets Day to bring together shareholders, company executives and analysts at the New York Stock Exchange.

The company plans to offer updates of results, ongoing projects and of plans for potential new paths to revenue, including trials in diagnosing lung cancer.

Quick facts: VolitionRx

Price: 4.48 USD

Market: NYSEMKT
Market Cap: $184.09 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

1 week, 3 days ago

2 min read